Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials

Aim: To assess the efficacy and safety of Dipeptidyl Peptidase IV (DPP-4) inhibitors in patients with Type-2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) using level 1 evidence.Methods: The Cochrane and PubMed databases were searched from inception until January 1, 2022.RCTs that studied the efficacy and safety of DPP-4 inhibitors in diabetic patients with CKD were included.The primary efficacy outcome was assessed as the mean difference between HbA1c at the beginning and the end of each study for each arm, and the primary safety outcome was assessed as the incidence of adverse events and severe adverse events in each study.Results: Twenty-one studies satisfied the pre-defined eligibility criteria.In assessing the efficacy of DPP-4 inhibitors in the treatment of T2DM and CKD, a total of 2917 patients under the DPP-4 inhibitors group and 2377 patients under the control group were included; The mean difference between the HbA1c of DPP-4 Inhibitor and the control group was -0.5295 with a 95% CI of -0.5337 to -0.5252.The included studies had high heterogeneity p < 0.00001 and I 2 = 99%.In assessing the safety outcome and tolerability of DPP-4 inhibitors, a total of 8138 patients under the DPP-4 inhibitors group and 7517 patients under the control group were included; the odds ratio of adverse events between both groups was 0.9967 with a 95% CI of 0.9967 to 1.1047.The included studies had low heterogeneity p = 0.25 and I 2 = 15%.The overall effect, Z = 0.06 (p = 0.95), was insignificant.Conclusion: Patients suffering from both T2DM and CKD exhibited a significantly enhanced glycemic control when treated with DPP-4 inhibitors in comparison to the control group.Furthermore, no significant difference in the incidence of adverse events was observed between the DPP-4 inhibitors and the control group.